OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

PASADENA, Calif. - EntSun -- July 5, 2019; Pasadena, U.S. - OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that it was honored as a Red Herring Top 100 North America Award winner recognizing the continent's most exciting and innovative private technology companies. After being recognized with the Red Herring Top 100 Europe Award earlier this year, this is now the second recognition obtained by Red Herring.

The winners, celebrated at a special awards ceremony at the Westin Pasadena hotel, have been chosen from thousands of entrants, whittled down to hundreds making the trip to California. The ceremony, led by Red Herring chairman Alex Vieux, was preceded by two days of keynote speeches, discussions and finalist presentations.

Companies were judged by industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy, and market penetration. Winners ran the gamut of verticals, from FinTech and Marketing to Security, IoT, and many more industries.

Red Herring's editors have been evaluating the world's startups and tech companies for over two decades. It gives them the ability to see through the industry's hype to pick firms that will continue on a trajectory to success. Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring's storied history.

"2019's crop of Top 100 winners has been among our most intriguing yet," said Vieux. "North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here in California, which is in many ways the heartland of the industry, has been a thrilling experience."

More on EntSun News

• Rock Band Black Halo Releases #MeToo Anthem, "In Death I Linger On"
• IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
• Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
• EnergyStrat Launches Global LNG Risk Outlook 2025–2030
• Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)

"What has excited me most is to see so many people forging niches in high-tech and cutting edge sectors," added Vieux. "Some of the technical wizardry and first-rate business models showcased here at the conference has been fantastic to learn about. We believe OncoBeta® embodies the drive, skill and passion on which tech thrives. OncoBeta® should be proud of its achievement - the competition was incredibly strong."

"Being named as one of the Red Herring's Top 100 North America award winner in addition to the Top 100 Europe is a great honor for us." states Shannon D. Brown III, CEO of OncoBeta®. "The spirit of the award aligns perfectly with our team's mission in the fight against non-melanocytic skin cancer (NMSC) with the Rhenium-SCT®."

The complete list of the 2019 Red Herring North America Top 100 Winners can be found here in alphabetical order: https://www.redherring.com/2019-rhna-top100-winners/

Red Herring's press release is available online at
https://www.redherring.com/red-herring-2019-top-100-north-america-winners-press-release/

About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium- SCT® utilizes the radioisotope Rhenium-188 in
an epidermal application with optimal properties for the treatment of NMSCs (nonmelanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with
a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

More on EntSun News

• DJ's GiggleWear Unveils 2025 Holiday Collection Inspired by Emerging Humor Trends
• Holiday Decorations Most Likely to Cause Injuries
• UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
• Star Wars Headliner Hayden Christensen To Attend FAN EXPO Cleveland, March 13-15, 2026
• Wavymy Hair Burmese Curly Wigs: Redefining What's Trending in Hair Fashion

About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta®`s outstanding
work has already been rewarded with several international recognitions such as "Top 20 MedTech Outlook Solution Provider in Europe", "Top 30 Ethical Companies of the Year 2019" by The Silicon Review Magazine and the "Top 100 Red Herring Europe Award". The Rhenium-SCT® is European CE certified and is filed for regulatory approval in several other countries outside the European  Union.

Find out more about the Rhenium-SCT® at https://www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or
circumstances after the date made, except as required by law.